JenaValve Technology
Latest round
- Series C
Last raised
- Dec 2021
Total raised
- $218M
Investors
- 16
About JenaValve Technology
JenaValve Technology, Inc.Founded in 2013 and headquartered in Irvine, US, JenaValve Technology, Inc. specializes in medical devices for heart conditions. The company has undergone strategic developments to enhance its product offerings but has not reported any significant operational pivots., Ltd.JenaValve is at the forefront of innovation in the medical device industry, specializing in advanced solutions for structural heart disease. Its core product, the Trilogy Heart Valve System, is specifically designed for patients with severe aortic regurgitation (AR) and aortic stenosis (AS) who are deemed high-risk for traditional surgical aortic valve replacement. The Trilogy System employs a transcatheter aortic valve replacement (TAVR) approach that enables less invasive procedures, thereby improving patient outcomes. This product is particularly aimed at healthcare providers and institutions that treat symptomatic patients across markets such as Europe and the United States, where they are actively engaged with cardiologists and surgical teams.JenaValve generates revenue primarily through the sale of its Trilogy Heart Valve System, which involves direct transactions with healthcare facilities and medical professionals. The transaction structure typically includes direct sales to hospitals and clinics that specialize in cardiac care, where the Trilogy System is integrated into their surgical offerings. Pricing plans for these medical devices are structured around the complexity of the procedures and the specific needs of the healthcare providers, optimizing patient care while ensuring compliance with regulatory standards. This approach not only allows JenaValve to establish strategic partnerships with key medical institutions but also facilitates the growth of its client base within the healthcare sector.Following the acquisition agreement with Edwards Lifesciences Corp in July 2024, JenaValve Technology, Inc. anticipates leveraging this partnership to enhance its structural heart portfolio, particularly in heart failure management. The acquisition will facilitate the development and introduction of new products tailored to meet evolving market demands.
Who invested in JenaValve Technology
16 investors across 7 rounds
See all investors in JenaValve Technology
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series C
Dec 21, 2021
Amount
$74M
Investors
Series C
Aug 7, 2015
Amount
$27M
Investors
Series C
Apr 8, 2014
Amount
$10M
Investors
Series C
Jul 23, 2013
Amount
$63M
Investors
Series B
Mar 1, 2010
Amount
$26M
Investors
Series A
Sep 21, 2007
Amount
$14M
Investors
Series A
Sep 1, 2006
Amount
$4.4M
Investors
Questions about JenaValve Technology
Who invested in JenaValve Technology?
JenaValve Technology has 16 investors on record across 7 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has JenaValve Technology raised?
JenaValve Technology has raised 7 venture rounds. Sign up free to see how much each round raised and the total.
When did JenaValve Technology last raise money?
JenaValve Technology's most recent round on record is a Series C, in Dec 2021.
What does JenaValve Technology do?
JenaValve Technology is a medical devices & equipment company.
Where is JenaValve Technology headquartered?
JenaValve Technology is headquartered in Irvine, US.
Which VCs invest in companies like JenaValve Technology?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back medical devices & equipment companies at JenaValve Technology's stage. Their profiles are linked below.
VCs backing medical devices & equipment startups at Series C
Raising like JenaValve Technology? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.